Sector News

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

April 10, 2021
Life sciences

That’s why its new strategic plan includes doubling the number of Black and Latinx directors and officers in leadership positions by 2025 and committing $1 billion in spending with diverse suppliers.

Genentech’s formalized plan comes in part as a response to a survey the company ran last year investigating health inequities. One of the key findings? One in three people in marginalized communities avoid participating in clinical trials, shun vaccines and reject testing because they don’t trust the industry.

Calling the findings “unacceptable,” Quita Highsmith, Genentech’s vice president and chief diversity officer, said bridges must be built to make patients “feel valued, respected, and understood. We must give them reasons to believe in the healthcare system. Until then, health equity cannot be achieved.”

Genentech knows from experience that concerted efforts around diversity can work. Its 10-year commitment to increasing the number of women in leadership roles and creating gender pay equity practices has resulted in 43% officer level representation by women, up from 24% in 2010.

Pay is essentially equal today at the pharma, where women make 99.6 cents for every dollar men earn—and also holds true for employees of color, who earn 99.5 cents for every dollar white employees make.

“As a company focused on serving an increasingly diverse world of patients and needing to drive innovation to tackle serious and life-threatening diseases, diversity and inclusion has been—and continues to be—a business imperative,” Highsmith said.

Genentech’s plan divides its goals into three focus areas: encourage belonging, address health inequity—especially in clinical research—and reach out to diverse communities.

The community outreach includes putting its money where its mouth is when it comes to health equity and charitable donations. Last year, Genentech spent $90 million, its highest annual amount to date, on patient support, STEM education and health equity programs.

Genentech’s commitment to diversity and inclusion is also on display in the company’s organizational chart, Highsmith said.

“While diversity teams are typically housed under the human resources umbrella, I report directly to our CEO—a strategic, purposeful and innovative reporting structure designed to enhance the impact of our diversity and inclusion efforts,” she said.

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.